HC Wainwright & Co. Reiterates Neutral on Lantern Pharma
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar has reiterated a Neutral rating on Lantern Pharma (LTRN), indicating no change in the firm's stance towards the company's stock.

April 25, 2024 | 10:36 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Lantern Pharma's stock rating was reiterated as Neutral by HC Wainwright & Co., suggesting stability in the company's outlook according to the firm.
The reiteration of a Neutral rating by a prominent analyst firm like HC Wainwright & Co. typically indicates that the firm does not foresee significant short-term price movement in either direction for Lantern Pharma's stock. This assessment is based on the current information available and the analyst's perspective on the company's future prospects.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100